Google hires Novartis to develop and produce smart contact lenses, which are intended to help people with a variety of medical conditions. For example, the contacts could help people who are farsighted by focusing a camera on objects and making them clearer, or they could be used to monitor glucose levels through the tears of people with diabetes. Google co-founder Sergey Brin says:
Our dream is to use the latest technology in the miniaturization of electronics to help improve the quality of life for millions of people. We are very excited to work with Novartis to make this dream come true.
Novartis announces that the FDA has approved Stalevo (carbidopa, levodopa and entacapone) tablets for patients with idiopathic Parkinson’s disease (PD) who experience signs and symptoms of end-of-dose “wearing off.” Stalevo contains levodopa, the most widely used agent for Parkinson’s disease, plus carbidopa and entacapone. While carbidopa reduces the side effects of levodopa, entacapone extends its benefits, permitting Parkinson’s disease patients to have an improved ability to perform everyday tasks and a reduction in symptoms associated with the disease.
Levodopa is recognized as the cornerstone of Parkinson’s disease therapy, but its long-term use is limited by its reduced ability to fully control Parkinson’s disease symptoms. By blocking the enzymatic breakdown of levodopa, Stalevo provides more levodopa to the brain for a longer period of time. Potential patient benefits include more “on” time during which Parkinson’s symptoms are well-controlled and daily activities are improved, and simpler, more convenient dosing.